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The complement system, a complex mixture of 
at least 15 sequentially activated plasma proteins, 
constitutes one of the primary effector systems of 
immunologically induced inflammatory reactions. 
The proteins are present in plasma in nonactivated 
form. Activation is by a series of specific proteo-
lytic reactions, which can be initiated by 
antigen-antibody complexes, fungal and bacterial 
substances, and certain cellular and humoral pro-
teolytic enzymes. 
The molecular events in the activation of the 
complement system can be divided between those 
involved in the classic activation mechanism (C1 , 
C4, C2, and (:3) and those which participate in the 
alternative or properdin pathway (IF , P , B, D). 
The latter pathway functions independently of C1, 
C4, and C2 but requires C3. The final step in the 
sequence, assembly of C5- C9, can be accomplished 
by both pathways. In addition , there are at least 
three normal plasma proteins which exert a regula-
tory effect on the complement reaction sequence 
[1 ]. 
The products and byproducts of complement 
activation have distinct biologic significance. They 
mediate structural and functional alterations of 
cellular membranes, and activation of specific 
cellular functions . 
PROTEINS OF THE CLASSIC PATHWAY AND THEIR 
ACTIVATIO N 
The classic pathway is composed of 11 distinct 
proteins [2 ,3] which differ markedly in their con-
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Abbreviations: 
DFP: diisopropyl phosphofluoridate 
NF: nephritic factor 
P: properdin 
- IF: initiating factor 
The components onne classic complement system are 
designated numerically, Cl, C2, C3, C4, C5 , C6, C7 , C8, 
C9; the three subcomponents of Cl are referred to as Clq, 
Clr, and CIs; and the components of the alternative 
pathway are designated by capital letters, IF, P , B, D. 
Physiologic fragments of components resulting from 
cleavage by enzymes which are indigenous to the comple-
ment system are distinguished by small arabic letters , 
e.g. , C3a and C3b. Enzyme activity is indicated by 
placing a bar above the designation of the component in 
which the activity resides. 
centrations in blood and in their physicochemical 
characteristics (Tab. ). 
The First Component (Cl) 
The first component of the classic pathway is 
present in its inactivated form as a calcium-
dependent macromolecular complex of three sub-
units , C1q, Clr, and CIs [4]. There have been 
reports of another subcomponent necessary for full 
C1 hemolytic activity [5]; however, C1 has been 
totally reconstituted from highly purified prepara-
tions of C lq and the proenzyme forms of C lr and 
CIs at concentrations comparable to those of the 
subunits in the euglobulin fraction of serum con-
taining Cl [6]. Clq is a glycoprotein with an 
unusual amino acid composition, containing 
hydroxylysine , hydroxyproline , and glycine [7]. 
This composition is similar to that of basal mem-
brane proteins [8]. The hydroxylysine residues 
appear to have glucosylgalactosyl residues coupled 
to them, another feature of basal membrane pro-
teins. The hemolytic activity of C1q is lost rapidly 
on digestion with collagenase [9] or heating [10], 
and hence a collagen-like sequence, which is es-
sential for its hemolytic activity, must be a struc-
tural feature of the molecule. Binding of C1q to IgG 
is less sensitive to collagenase or heating, suggest-
ing that the interaction between IgG and Clq may 
be through a noncollagen-like portion of the mole-
cule. Digestion with pepsin fragments the noncol-
lagen portion, with subsequent loss of binding [11]. 
The molecular weight (MW) of C lq is agreed to 
be close to 400,000 daltons [9,12,13 ]; however, 
there is some controversy as to the subunit struc-
ture [9,14]. Recent work has proposed that C1q is 
composed of nine non-covalently linked subunits of 
42,000 to 47,000 MW, consisting of six dimers of 
two nonidentical chains (A-B) and three dimers 
of two identical chains (C-C) [11] with MWs of 
24,000, 22,500, and 21,000, respectively [14]. Based 
on chemical data , a model for C1q has been 
proposed in which the collagen-like regions in each 
A, B, and C chain are combined to form a triple 
helical structure of the same type as is found in 
collagen. Each major triple helix is joined to 
another via the C-chain interchain disulfide bond 
to give a pair of 67,000 MW units [15]. The 
suggested structure of C1q fits with the biologic 
features such as the presence of six binding sites for 
immunoglobulins. 
C1r, first described by Lepow et al [16], was 
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TABLE. Physicochemical characteristics of proteins of the complement sys tem 
Approxi-
Electro- mate Molecular serum NameD 
weight phoret ic concen - Fragments 
mobility tration 
Classic activation: 
C1q 400,000 1'2 
C1r 168,000 (3 
CIs 86,000 ex 
C4 «(31E) 206,000 (3 1 
C2 117,000 (3 2 
C3 «(31C) 180,000 (31 
Alternativ e pathway 
activation: 
Properdin 186,000 1'2 
Initiating factor 150,000 1' 1 
(nephritic factor 
analog, IF) 
Factor D 25 ,000 ex2 
(C3PAase, GBGase) 
Factor B 93,000 (3 2 
(C3PA, GBG) 
Terminal sequence: 
C5 «(31F) 185,000 (31 
C6 95,000 (32 
C7 110,000 (3 2 
C8 163,000 1'1 
C9 79,000 ex 
a Synonyms are given in parentheses 
found to activate CIs and to hydrolyze some 
synthetic ester substrates ; therefore it was thought 
to be C1f [17] . More recently, both a precursor and 
an active form of C1r have been isolated in highly 
purified forms. C1r has a MW of 188,000 and an 8 
val ue of 7.5 which fell to 68 upon activation by 
trypsin [18]; this C1f was no longer able to form a 
complex with C1q and CIs in Ca 2+ . In contrast, 
spontaneously activated Clf has a MW of 168,000 
and retained the power to recombine with C1q and 
CIS [19] . Under dissociating conditions C1r is a 
single polypeptide chain of approximately 83,000 
MW; but activated C If consists of two polypeptide 
chains of MWs 56,000 and 27 ,000 [20]. Activation 
must therefore involve cleavage of at least one 
polypeptide bond in the proenzyme. The active 
site of C1r is located in the 27,000 MW fragment, 
as evidenced by its binding of [32P ]diisopropyl 
phosphofluoridate (DFP) [20]. DFP treatment in-
hibits CIs activation by C1r [21]. 
CIS has been identified as the component 
carrying the major esterase activity of C1 [16 J. 
Purified CIS will hydrolyze C4 and C2 and a 
variety of synthetic peptide esters, such as the 
N-acetyl-L-arginine ethyl ester, and the p-toluene-
sulfonyl-L-arginine methyl esters of both aromatic 
basic amino acids [22]. 
CIS and CIs have both been purified. Although 
CIs has been reported to activate spontaneously, 
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CIs consists of a single polypetide chain of 83,000 
MW . CIS activated by Clr has a similar MW, but 
gives two peptide chains of 56,000 and 27,000 MW 
under dissociating conditions [23,24]. DFP inhibits 
both the esterase and hemolytic activity of ClS. 
Using 32P-labeled DFP, it was shown that a single 
molecule is bound per molecule of CIS. The labeled 
DFP was found to be present in the 27 ,000-MW 
fragment [25], which must therefore contain the 
enzymatic active site. A study of the sequence of 
this peptide disclosed a similarity to the sequence 
found in the active site of other serine esterases 
such as trypsin , chymotrypsin, thrombin , and 
plasmin [11]. 
The Second Component (C2) 
C2 is a trace protein in blood. It has a MW of 
117,000 and an 8 value of 4.5. CIS is known to split 
C2 into two fragments , C2a and C2b; however, 
these products have not been either isolated or 
analyzed. 
The Third and Fifth Components (C3 and C5) 
C3 and C5 have similar MWs (180,000) and both 
contain two covalently linked chains of 110,000 and 
70,000 MW [26,27]. C3 and C5 are substrates of 
two different enzymes formed consecutively during 
complement activation. A small fragment of the 
110,OOO-MW chain is split in each case to give 
fragments C3a and C5a, leaving the major frag-
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ments C3b and C5b with a transient capacity to 
bind to membranes. In addition, C3b has a binding 
region for properdin (P) [28]; and C5b for C6, C7, 
and C8 [29]. 
The Fourth Component (C4) 
C4 is one of the two natural substrates of CIS, 
with MW 206,000. Both a two [30] and a three [31] 
covalently linked chain structure have been postu-
lated for C4. Mild reduction of C4, followed by gel 
filtration , has recently confirmed the three-chain 
structure [32]. The isolated polypeptide chains 
have MWs of 100,000, 76,000, and 33,000, respec-
tively. 
C IS splits C4 into at least two portions , C4b and 
C4a [33, 34]. C4a, a 6,000-MW fragment, is derived 
from the 100,000-MW chain in a limited proteo-
lytic reaction [31] which is thought to involve a 
single peptide cleavage. 
The Sixth to Ninth Components (C6-C9) 
C6, C7, C8, and C9 have been less well charac-
terized. They react reversibly with C5, forming a 
product with a sedimentation velocity of approxi-
mately 15S, which is slower than that obtained 
with the activated molecules , 26S [29]. 
The Classic Activation Mechanism 
C1 activation occurs specifically by binding of 
the C1q subunit to the Fc portion of aggregated 
immunoglobulin [35] . However, under certain con-
ditions , the proresses of binding and activation can 
be separated [36]. The specificity of C1 binding 
and activation is high; full activation follows 
binding of C1 to aggregates of the IgM and IgG 
immunoglobulins (human IgG 1, IgG2, and IgG3) 
but little , if any, follows binding to monomers . 
N ei ther IgA, IgD [37], nor IgE [38] binds or 
activates Cl. 
The very unusual hexamer structure of C1q, 
correlated with its ability to combine with four to 
six IgG molecules [7], suggests that the binding 
sites of C1q may be located in the peripheral 
globular portions of the molecule [ll] (Fig. 1). 
Although there is no evidence of the development 
of enzymatic activity in C1q on binding, it results 
in C1r activation. It is possible that this reaction 
may proceed through a conformational change in 
the globular portion of the C1q molecule, which is 
transmitted through the relatively rigid collage-
nous portion to the central area to which C1r may 
be bound. Activation of C1r leads to activation of 
the proenzyme CIs [24]. 
In the intact C1 molecule, the conditions for CIs 
activation are unusual in that the enzyme (CIr) 
and the substrate (CIs) are believed to be present 
in an equimolar ratio. However, using isolated C1r 
and CIs in the absence of Ca 2+, it has been possible 
to demonstrate that 1 mole of Clf can activate 
several moles of CIs. Addition of Ca2+ restricts 
activation to an equimolar ratio [21]. Since Ca His 
an intrinsic component of the intact C1 molecule, 
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FIG. 1. Activation of the classic pathway of the com-
plement system. 
its biologic role may be visualized as twofold: first , 
it may be an essential component in C1r activation 
by forming a stable complex of C1q-C1r ; secondly, 
it may restrict CIs activation and, in this manner, 
act as a controlling mechanism in the activation of 
the classic component system. 
There are several reports of nonspecific activa-
tion of C1 by membranes of different origins [39]. 
In addition , plasmin and trypsin [40] are assumed 
to be responsible for the nonspecific activation of 
Cl. 
It has long been appreciated that C4 precedes C2 
in the immune hemolytic sequence, even though 
both are natural substrates of CIs [41]. The reason 
for this order became aEparent with the finding 
that the activity of C1 upon C2 is markedly 
enhanced by the prior interaction of CI, either free 
in the fluid phase or cell bound (EACi), with C4. It 
was postulated that the ci -C4 interaction alters 
the configuration of the CI molecule, exposing the 
enzymatic site responsible for C2 utilization [42]. 
Studies on the species specificity of the compo-
nents involved and some physicochemical proper-
ties support this view. CI of human origin inacti-
vates guinea-pig C4 far less than it inactivates 
human C4. Similarly, guinea-pig C4 fails to en-
hance human C2 utilization and, indeed, causes 
inhibition. C1 heated at 56°C for 30 min loses its 
hemolytic activity but retains its capacity to bind 
to antibody-coated erythrocytes and to hydrolyze 
C4 but not C2. This suggests that the binding of CI 
to sensitized erythrocytes is relatively heat stable, 
as is the esterase activity, but that the cLi site 
which facilitates hydrolysis of C2 is heat labile 
[42]. The fact that heat-treated ci' can still be 
bound by sensitized erythrocytes, a property asso-
ciated with the subunit C1q, and that it retains its 
esterase activity, due to the ClS subunit, suggests 
that the heat-labile C4 binding site will be in Clf. 
In contrast to these data, a C4 binding site on CIs 
distinct from the enzymatic site has been postu-
lated [43]. 
The action of the C 1 enzyme on C4 leads to 
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cleavage of C4 and physical uptake of the major 
fragment, C4b, onto membranes [44]. The C14 
complex generated acts on C2, allowing the major 
fragment of C2 (C2a) to fuse with C4b, resulting in 
the formation of a protein-protein complex C142, 
the classic C3 convertase, with new enzymatic 
activity [45]. This enzym~is unstable at 37°C, 
reverting to the original C 14 state [46]; the addi-
tion of fresh C2 restores its C3-converting activity. 
C3 convertase acts on C3, inducing the cleavage of 
the C3 molecule into two fragments, C3a and C3b. 
During this step, the major fragment, C3b, either 
associates with its activating enzyme, generating 
C1423, or appears in the fluid phase as an inactive 
product, C3i. The lesser fragment, C3a, is released 
into the fluid phase. The complex formed, C1423, 
acquires a new enzymatic activity (C5 convertase) 
which has as substrate C5 [47,48 J. Although fluid-
phase C3 convertase is capable of initiating these 
reactions, a cell-bound position for C3 convertase, 
as on EAC142, favors the deposition of the cleavage 
products C3b and C5b on the cell surface and the 
assembly of C5-C9 on the membrane in a cytolyti -
cally active form. 
PROTEINS OF THE ALTERNATIVE PATHWAY AND 
THEIR ACTIVATION 
In 1954, Pille mer and his associates [49] de-
scribed a mode of complement utilization initiated 
by a naturally occurring lipopolysaccharide, zymo-
san, by which the C3 contained in serum was 
inactivated to a much greater extent than were C1, 
C4, and C2; the mechanism was independent of 
specific antibodies and involved a distinct serum 
protein, properdin. The action of properdin 
required Mg2 +, a heat-labile factor (Factor B) , a 
hydrazine-sensitive factor (Factor A), and a factor 
present in the pH 5.5 euglobulin fraction of serum. 
This pattern of complement utilization differs 
markedly from that observed with the classic C3 
convertase, and it is attributed to activation of C3 
and the terminal complement sequence via the 
properdin system, which includes both an activa-
tion pathway and an amplification loop. At least 
five distinct proteins have been recognized as part 
of the system (Tab.). 
Initiating Factor (IF) 
Although originally properdin was described as 
the IF of the alternative pathway, recent data 
indicate that this protein does not establish the 
initial interaction with the activators of the alter-
native pathway. A trace protein in normal human 
serum, identical to a factor described in patients 
with hypocomplementemic glomerulonephritis , 
nephritic factor (NF) [50], appears to be an essen-
tial early-acting component of the system [51]. 
This normal serum protein, called the initiating 
factor, was found to be a heat-stable 6-7S pseudo-
globulin with the electrophoretic mobility of a 
'Yl-globulin. Antiserum to NF detects IF; thus, IF 
and NF may represent identical serum proteins 
[51 ]. 
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Properdin (P) 
Activated properdin CP} is a highly basic globu-
lin [52] with MW 184,000, consisting of four 
non-covalently bound subunits of similar MW 
(46,000-53,000). The subunits can recombine to 
form 88,000-MW dimers which partially retain the 
antigenic and biologic properties of the native 
molecule [53]. Properdin exists in serum in precur-
sor form and activation proceeds without appreci-
able .changes in its molecular size. 
Factor B 
This (3 globulin (C3 pro activator, C3PA; glycine-
rich (3 globulin, GBG) [54,55] is the precursor of a 
C3 cleaving enzyme. It consists of a single peptide 
chain with a MW of 93,000; upon activation, it is 
split into two antigenic ally distinct fragments, one 
behaving as a 63,000-MW 'Y-globulin and the oth~r 
as a 30,000-MW a-globulin. The I' fragment (B) 
was originally designated C3 activator (C3A) and 
when isolated, retains some of its ability to cleave 
C3 and hydrolyze N-a-acetyl-glycyl-L-lysine-meth-
yl ester [56] . 
Factor D (C3 Proactivator Convertase, C3PAase) 
This is a trace protein of serum which has been 
recently isolated in its active CD) [57] and precur-
sor (D) forms [58]. Although isolated factor D is 
readily activated by trypsin [59], its physiologic 
mechanism of activation has not yet been eluci-
dated. Factor :is, but not D, is susceptible to 
inactivation by DFP. It has been functionally 
identified with C3PAase [60]. 
C3 (Factor A) 
The hydrazine-sensitive factor of the properdin 
system, factor A, has been shown to be identical to 
C3 [60,61] . Restoration of factor A activity in 
serum rendered deficient by treatment with 
hydrazine can be demonstrated upon addition of 
purified C3. Treatment of purified C3 with hydra-
zine abolished its C3 hemolytic activity and factor 
A function. 
Activation Mechanism 
Although antigen-antibody complexes prepared 
from guinea-pig 1'1 antibodies [62], aggregated 
F(ab')2 fragments [63], and aggregated human IgA 
and IgE myeloma proteins [38] are capable of 
activating the alternative pathway, direct nonim-
munologic activation by endotoxin or a variety of 
bacterial lypopolysaccharides also occurs [64]. 
Activation of the alternative pathway by zymo-
san appears to require IF early in the sequence 
(Fig. 2). Serum depleted of IF by immunoadsorp-
tion does not support C3 consumption upon incu-
bation with inulin or zymosan in the presence of 
normal levels of P, B, and C3. Addition of purified 
IF results in the consumption of C3. Using fluores-
ceinated antisera to C3 and P, it has been shown 
that C3 is deposited if zymosan is incubated in 
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altered IgA. F(ab')2 ' polysaccharides 
(). IIF 
"'- ~ IF C~~ ~I 
Mg l C3.B. D Mg" 
C31FB C3 1 
I i _ +t- C 5, 6 , 7,8 , 9 
~ 5-C3 B,o Mg > 5-C3B ~5-C5-9 1 'B"'" r P C3 
C 3 . P -----..5 - C 3 p'!<==/=;;:;.> 5 - C3 P B 
B,D Mg* ~6C3 _ 
5 = Site on a membrane 
C5 C 3 
5-C 3 
5-C5 yc 6.7.8 ,9 
S-C5-9 
FIG. 2. Activation of the alternative pathway of the 
complement system. 
serum depleted of C4 and P, but not if the serum is 
free of B, :5, or IF. P is detected on zymosan only 
when the conditions allow C3 deposition [51] . 
From these experiments it can be concluded that 
IF, in cooperation with Band D, form a C3 
convertase, generatin[ C3b to which P is capable of 
binding. Binding of P to C3b [65], but not of P 
[51 ,66], has bee~ demonstrated using purified P 
and ~ and EAC43. Activ~tion of P is initiated by 
EAC43 and requires B, D, and Mg2+. Since P is 
bound to preformed EAC43B in the presence of 
EDTA (ethylenediamine tetraacetate), EAC43B 
must be the P-activating principle [67]. Binding of 
P stabilizes the enzymatic site by prolonging the 
decay rate of the C3]3 enzyme [65,66J. 
Large amounts of P and B with C3 in the absence 
of is form a C3 convertase in which cleavage </f B 
does not demonstrably occur, although the active 
site is available. The presence of D augments 
initial cleavag~ of C3 by fully exposing the active 
site of Band P stabilizes it [28]. 
The C3b Amplification Mechanism 
In addition to its function as a Preceptor, C3b 
induces the formation of a P-independent .C3 
cleaving activity (Fig. 2). This function of C3b has 
been delineated by- independent, but converging, 
studies of the properdin factors [68 J, of the sera of 
patients deficient in C3 [69], or C3b in activator 
[70], and on the mechanism of action of an 
anticomplementary factor in cobr~ venom [71]. 
The presence of C3b, together with D, initiates the 
activation of B and the subsequent cleavage of this 
protein into its 'Y £!nd a fragments [57]. The 
enzyme responsible, D, does not by itself act on B 
as it requires C3b; thus, C3b modulates the 
enzyme-substrate interaction between D and B 
and becomes instrumental in activating a system 
which acts on C3. C3B, whether present in the 
fluid phase or bound to a membrane as EAC3B is 
- ' 
unstable at 37 ac because of the B decay [28]. 
Assembly of C3B on the surface of cells induces ly-
sis when the components C3-C9 anre added [72,73]. 
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THE TERMINAL ATTACK SEQUENCE 
Attack of C5 by either the classic C5 convertase 
(C1423) or the alternative pathway convertase 
(C3PB) initiates a process which results in the 
assembly of the multimolecular complex C5-C9 
(Fig. 3). C5b, the larger of the two fragments 
produced by C5 cleavage, interacts with C6 to form 
a Cg6 complex [74J. Reaction of membrane-bound 
Cg6 with C7 leads to the formation of a stable C567 
co_mplex on the cell surface [75]. In theJ1uid phase, 
C56 reacts with C7 to form nascent C567 which is 
transiently capable of binding directly to cell 
surfaces which have not reacted with antibody or 
the earlier components of complement [76,77]. The 
trimolecular complex C567, either bound to a 
membrane or in free solution, interacts with C8 in 
a purely absorptive process without any further 
enzymatic activity. C8 in the C5-C8 complex binds 
C9, completing the formation of the molecular 
assembly responsible for membrane damage [29]. 
The binding capacity of nascent C5-C9 decays 
rapidly with the accumulation of biologically inac-
tive products in the fluid phase [78,79]. 
Experimental evidence suggests that C8 is the 
molecule which executes the cytolytic function of 
the terminal complement sequence . Whereas the 
membrane of a target cell carrying C567 remains 
intact, it becomes altered upon absorption of C8. 
In the absence of C9, highly purified C8 causes the 
cells to undergo'low-grade lysis [80]. The role of C9 
may be visualized as the enhancement of C8 
function . 
CONTROL MECHANISMS 
The complement reaction sequence is subject to 
controlling processes which are inherent in its 
mode of activation. The rapid decay of enzymatic 
and binding sites restricts complement action. The 
decay of C2 and 13 in the C42, C423, and C3B 
complexes limits the activation of the late-acting 
components. Other controlling mechanisms are the 
result of natural inhibitors or inactivators. These 
are serum-proteins which combine with, or destroy 
enzymatically, the activated forms of certain of the 
activated components. The CI inhibitor (CIINH) 
blocks the enzymatic activity of ci and cI~ [81]. 
It inhibits stoichiometrically the hemolytic and 
enterolytic activity of CI [82] by binding to the 
ClaSSi cal Pathway 
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FIG. 3. Terminal sequence of complement activation . 
Attack mechanism. 
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enzymatic site of CIs [83] to form an inactive 
complex. The C3b inactivator (C3bINA) [84,85] 
splits cell-bound or fluid-phase C3b into two frag-
ments, C3c and C3d. As a result, the hemolytic 
activity of C423 and the C3b-dependent activation 
of factor B are destroyed [60,86], serving to control 
the amplification loop in which these factors par-
ticipate. 
In addition, the biologic functions mediated by 
C3b, immune adherence and phagocytosis [87], are 
suppressed. Both C3a and C5a are controlled by 
serum carboxypeptidase B, also called ana-
phylatoxin inactivator. This enzyme is responsible 
for total suppression of anaphylatoxin activity in 
human serum. It inactivates the C3a and C5a 
peptides by removal of the COOH terminal argi-
nine residue [88]. 
BIOLOGIC FUNCTIONS OF THE COMPLEMENT SYSTEM 
The potential biologic meaning of the comple-
ment system is no longer only in terms of cytotoxic-
ity [89,90]. Cleavage products, fluid-phase com-
plexes, and cell-bound components give rise to 
important biologic effects. 
Among the fragments produced during comple-
ment activation, a vasoactive peptide [91], distin-
guishable from bradykinin, has been isolated from 
the plasma of patients with angioedema of the 
hereditary type. This material may represent a 
previously unrecognized cleavage product of C2 
and has been temporarily termed C-kinin. C3a and 
C5a have similar biologic activities in that they 
both release histamine from mast cells , contract 
isolated guinea-pig ileum [92,93], and produce a 
local wheal when injected intracutaneously into 
the skin [94,95]. Their mode of action seems to be , 
at least in part, due to binding to receptors on the 
mast cell membrane [96]. In addition , C3a and C5a 
activate a proesterase of polymorphonuclear leuko-
cytes [97], inducing directed migration of these 
cells. Eosinophils [98] and mononuclear leukocytes 
[99] have subsequently been shown to respond in 
similar fashion. C567 _[100] and the alternative 
pathway convertase C3B [101] also exhibit chemo-
tactic activity. 
Binding of major fragments of the components to 
target cells or other particles has important biolog-
ic effects. Enhancement by C 1 and C4 of the 
capacity of antibodies to neutralize the herpes-
simplex virus has been demonstrated [102]. Bound 
C3b [103] and, to a lesser extent, C4b [104] possess 
second binding sites which react with specific 
receptor sites on the surface of a variety of mam-
malian cells in the immune adherence phenome-
non. This reaction facilitates phagocytosis by poly-
morphonuclear leukocytes, mOQocytes, and macro-
phages [87]. Recently it has been suggested that 
the opsonic fragment of C3 is not the fragment 
defined as C3b but a smaller derivative of C3b 
[105 ]. 
Receptors for fluid-phase or bound C3, C4, and 
their fragments, C4b, C3b, and C3d, have been 
described on normal B-lymphocytes and cultured 
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lymphoblastoid cells [106,107]. It has postulated 
that C3b binding triggers B-cell activation either 
directly or indirectly by facilitating cell coopera-
tion [108]. 
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DISCUSSION 
Austen: Is factor B found in lesions of dermatitis 
herpetiform is ? 
Provost: Biopsy of lesions in dermatitis herpetiformis 
invariably fails to reveal by direct immunofluorescent 
techniques the deposition of IgA complement compo-
nents as well as properdin and properdin Factor B. 
Positive fluorescence is found in periblister areas and 
normal skin. 
Lazarus: What is the mechanism of membrane lysis 
by complement? 
Gigli: C8 in combination with C9 may play an 
important role in the production of membrane damage 
seen in complement lysis. 
Harber: The size of the hole in colloid osmotic 
hemolysis has been demonstrated to be less than lOA. 
The complement hole is 3 to 10 times larger in electron 
micrographs. Colloid osmotic hemolysis is compatible 
with damage to the ATP "pump" and rapid K+ loss. This 
has not been shown to be applicable in complement lysis . 
Cohen: In immunologically related inflammatory 
processes there is a propensity of specific-type circulating 
leukocytes and cellular counterparts within tissues to 
localize, accumulate, and/or interact in specific organs or 
tissues and to segregate with other cell types. This often 
occurs without apparent relationship to exact areas of 
immune complex deposition or inactivation of putative 
Sept. 1976 
responsible chemical mediators. On the supposition that 
complement fragment cellular . attachments could be 
relevant, can you tell us for which cell types there is 
definite evidence for receptors and for which products of 
the complement cascade? 
Gigli: Complement receptors have been found in a 
variety of lymphoid cells . The receptor for Clq does not 
seem to play a significant role. B-Iymphocytes have 
receptors for native C4 and C3 and for their major 
fragments C4b, C3b, C4d, and C3d . Bokisch recently 
reported that 40 to 50% of human peripheral blood 
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lymphocytes had Factor B detectable on their surface. 
Austen: A chemotactic factor must work in concert 
with a permeability factor which creates a marginating 
cell pool which then responds to the specificity of the 
chemotactic factor. 
Krueger: Do complement component fragments , 
namely, C5a and C3a, interact with specific receptors on 
any cell surfaces? Can these factors be identified by 
imm unofl uorescence? 
Gigli: With fluorescein-conjugated antisera, C3a and 
C5a have been demonstrated to bind to mast cells . 
